2026 Q1 -tulosraportti
84 päivää sitten
‧1 t 2 min
7,95 DKK/osake
Viimeisin osinko
3,58%Tuotto/v
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 5.8. | 7 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·6 min sittenIt will be exciting to see how the publication of phase 3 data for retatrutide is received. Much of the expectation for retatrutide and the rest of the pipeline is already priced into the current share price. At the same time, despite the overreactions, NVO still has a promising peptide in cagrilintide and CagriSema. One can only hope that future trials will be designed to show the potential of CagriSema.
·1 t sittenEli Lilly stated in its latest financial report that 65 percent of the company's revenue can be attributed to Mounjaro and Zepbound, while approximately 60 percent of Novo's revenue can be attributed to Wegovy, Ozempic, and the pill Rybelsus, all of which are based on the active substance semaglutide. The active substance in Eli Lilly's product is called Tirzepatide. Novo Nordisk has scored some small victories over Eli Lilly in recent months. Novo was the first to launch its weight loss pill in the USA some months before Eli Lilly. Novo Nordisk, on the other hand, has totally lost the battle to its arch-rival in the stock market. In the last five years, Eli Lilly's share price has skyrocketed by approximately 370 percent, while Novo Nordisk's share price has increased by a meager approximately 16 percent. A share price is in reality an expression of the view on Novo Nordisk and Eli Lilly in the long term. A share price should ideally reflect all available knowledge. The stock markets' verdict right now is that Eli Lilly appears to be winning the battle for the lead position in the American market, that Eli Lilly is also set to win the battle to develop new products and thus is also set to perform better in the fight against generic manufacturers. I wrote approximately 14 days ago that I bought 500 pcs. Novo – I'm keeping them.
It is difficult to know who wins the obesity battle. Illy is priced to win and Novo to lose. I have Novo as there is more to gain in case the market is wrong. Realistically, I think there is room for both and a couple more.
·1 t sitten · MuokattuMany of us are often ''accused'' of *hyping Novo. I could understand the accusation if Novo traded at 1200 and we were over-optimistic. Some/many of us are optimistic about a fantastic future for a fantastic company Novo, but with a share price that, in my opinion, has been ''slaughtered'' completely(228) I hope Q2, coming soon, is another piece falling into place and shows what a quality company Novo is, and what a gigantic growth market they are facing. 👍 All loyal shareholders deserve that👍 *The word hype comes from English “to hype”, which means to promote or create buzz in a very enthusiastic way.
·3 t sitten · MuokattuLooks strong leading up to the earnings report. Don't disappoint us now, Mike, with the figures on Wednesday, Just slightly less negative figures = all good 😊
- ·3 t sitten · MuokattuWhen the price slides back minimally, it is quickly absorbed by buyers👍 good signs!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
84 päivää sitten
‧1 t 2 min
7,95 DKK/osake
Viimeisin osinko
3,58%Tuotto/v
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·6 min sittenIt will be exciting to see how the publication of phase 3 data for retatrutide is received. Much of the expectation for retatrutide and the rest of the pipeline is already priced into the current share price. At the same time, despite the overreactions, NVO still has a promising peptide in cagrilintide and CagriSema. One can only hope that future trials will be designed to show the potential of CagriSema.
- ·1 t sittenEli Lilly stated in its latest financial report that 65 percent of the company's revenue can be attributed to Mounjaro and Zepbound, while approximately 60 percent of Novo's revenue can be attributed to Wegovy, Ozempic, and the pill Rybelsus, all of which are based on the active substance semaglutide. The active substance in Eli Lilly's product is called Tirzepatide. Novo Nordisk has scored some small victories over Eli Lilly in recent months. Novo was the first to launch its weight loss pill in the USA some months before Eli Lilly. Novo Nordisk, on the other hand, has totally lost the battle to its arch-rival in the stock market. In the last five years, Eli Lilly's share price has skyrocketed by approximately 370 percent, while Novo Nordisk's share price has increased by a meager approximately 16 percent. A share price is in reality an expression of the view on Novo Nordisk and Eli Lilly in the long term. A share price should ideally reflect all available knowledge. The stock markets' verdict right now is that Eli Lilly appears to be winning the battle for the lead position in the American market, that Eli Lilly is also set to win the battle to develop new products and thus is also set to perform better in the fight against generic manufacturers. I wrote approximately 14 days ago that I bought 500 pcs. Novo – I'm keeping them.It is difficult to know who wins the obesity battle. Illy is priced to win and Novo to lose. I have Novo as there is more to gain in case the market is wrong. Realistically, I think there is room for both and a couple more.
- ·1 t sitten · MuokattuMany of us are often ''accused'' of *hyping Novo. I could understand the accusation if Novo traded at 1200 and we were over-optimistic. Some/many of us are optimistic about a fantastic future for a fantastic company Novo, but with a share price that, in my opinion, has been ''slaughtered'' completely(228) I hope Q2, coming soon, is another piece falling into place and shows what a quality company Novo is, and what a gigantic growth market they are facing. 👍 All loyal shareholders deserve that👍 *The word hype comes from English “to hype”, which means to promote or create buzz in a very enthusiastic way.
- ·3 t sitten · MuokattuLooks strong leading up to the earnings report. Don't disappoint us now, Mike, with the figures on Wednesday, Just slightly less negative figures = all good 😊
- ·3 t sitten · MuokattuWhen the price slides back minimally, it is quickly absorbed by buyers👍 good signs!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 5.8. | 7 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 |
2026 Q1 -tulosraportti
84 päivää sitten
‧1 t 2 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 5.8. | 7 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 |
7,95 DKK/osake
Viimeisin osinko
3,58%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·6 min sittenIt will be exciting to see how the publication of phase 3 data for retatrutide is received. Much of the expectation for retatrutide and the rest of the pipeline is already priced into the current share price. At the same time, despite the overreactions, NVO still has a promising peptide in cagrilintide and CagriSema. One can only hope that future trials will be designed to show the potential of CagriSema.
- ·1 t sittenEli Lilly stated in its latest financial report that 65 percent of the company's revenue can be attributed to Mounjaro and Zepbound, while approximately 60 percent of Novo's revenue can be attributed to Wegovy, Ozempic, and the pill Rybelsus, all of which are based on the active substance semaglutide. The active substance in Eli Lilly's product is called Tirzepatide. Novo Nordisk has scored some small victories over Eli Lilly in recent months. Novo was the first to launch its weight loss pill in the USA some months before Eli Lilly. Novo Nordisk, on the other hand, has totally lost the battle to its arch-rival in the stock market. In the last five years, Eli Lilly's share price has skyrocketed by approximately 370 percent, while Novo Nordisk's share price has increased by a meager approximately 16 percent. A share price is in reality an expression of the view on Novo Nordisk and Eli Lilly in the long term. A share price should ideally reflect all available knowledge. The stock markets' verdict right now is that Eli Lilly appears to be winning the battle for the lead position in the American market, that Eli Lilly is also set to win the battle to develop new products and thus is also set to perform better in the fight against generic manufacturers. I wrote approximately 14 days ago that I bought 500 pcs. Novo – I'm keeping them.It is difficult to know who wins the obesity battle. Illy is priced to win and Novo to lose. I have Novo as there is more to gain in case the market is wrong. Realistically, I think there is room for both and a couple more.
- ·1 t sitten · MuokattuMany of us are often ''accused'' of *hyping Novo. I could understand the accusation if Novo traded at 1200 and we were over-optimistic. Some/many of us are optimistic about a fantastic future for a fantastic company Novo, but with a share price that, in my opinion, has been ''slaughtered'' completely(228) I hope Q2, coming soon, is another piece falling into place and shows what a quality company Novo is, and what a gigantic growth market they are facing. 👍 All loyal shareholders deserve that👍 *The word hype comes from English “to hype”, which means to promote or create buzz in a very enthusiastic way.
- ·3 t sitten · MuokattuLooks strong leading up to the earnings report. Don't disappoint us now, Mike, with the figures on Wednesday, Just slightly less negative figures = all good 😊
- ·3 t sitten · MuokattuWhen the price slides back minimally, it is quickly absorbed by buyers👍 good signs!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt